Camp4 Therapeutics (CAMP) Return on Capital Employed (2024 - 2026)
Camp4 Therapeutics (CAMP) posted Return on Capital Employed of 55.29% for Q1 2026, up 8.91% sequentially from 60.7% in Q4 2025, and up 2789.0% YoY from 1.91% in Q1 2025.
Camp4 Therapeutics (CAMP) Return on Capital Employed (2024 - 2026) Analysis & Trends
Camp4 Therapeutics has reported Return on Capital Employed for 3 years, with the latest figure at 55.29% in Q1 2026.
- Quarterly Return on Capital Employed rose 2789.0% year-over-year to 55.29% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 55.29% (up 2789.0% YoY) and the FY2025 annual result came in at 63.67%, up 2942.0% from the prior year.
- Return on Capital Employed advanced to 55.29% in Q1 2026 per CAMP's latest filing, from 60.7% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 55.29% in Q1 2026 and troughed at 131.93% in Q4 2024.
- A 3-year average of 87.91% and a median of 85.74% in 2025 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2025 and 2026: Return on Capital Employed jumped 7124 bps in 2025, then surged 2789 bps in 2026.
- Over 3 years, Return on Capital Employed stood at 131.93% in 2024, then soared by 54 bps to 60.7% in 2025, then rose by 9 bps to 55.29% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 55.29%, 60.7%, and 88.32% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Camp4 Therapeutics | 282.48 Mn | 282.48 Mn | - | -65.85% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -65.85% |
| Mar 31, 2026 | -55.29% |
| Dec 31, 2025 | -60.70% |
| Sep 30, 2025 | -88.32% |
| Jun 30, 2025 | -108.03% |
| Mar 31, 2025 | -83.17% |
| Dec 31, 2024 | -131.93% |